Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative drugs operate by mimicking the inherent actions of GLP-1, a hormone secreted by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these agents increase insulin release and suppress gluc

The management of diabetes continues to evolve with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant attention. These medications offer promising mechanisms for controlling blood sugar levels and potentially improve the lives of individuals living with diabetes